<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22945356</PMID><DateCompleted><Year>2013</Year><Month>05</Month><Day>16</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1748-7838</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>11</Issue><PubDate><Year>2012</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Cell research</Title><ISOAbbreviation>Cell Res</ISOAbbreviation></Journal><ArticleTitle>Coxsackievirus mutants that can bypass host factor PI4KIII&#x3b2; and the need for high levels of PI4P lipids for replication.</ArticleTitle><Pagination><StartPage>1576</StartPage><EndPage>1592</EndPage><MedlinePgn>1576-92</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/cr.2012.129</ELocationID><Abstract><AbstractText>RNA viruses can rapidly mutate and acquire resistance to drugs that directly target viral enzymes, which poses serious problems in a clinical context. Therefore, there is a growing interest in the development of antiviral drugs that target host factors critical for viral replication, since they are unlikely to mutate in response to therapy. We recently demonstrated that phosphatidylinositol-4-kinase III&#x3b2; (PI4KIII&#x3b2;) and its product phosphatidylinositol-4-phosphate (PI4P) are essential for replication of enteroviruses, a group of medically important RNA viruses including poliovirus (PV), coxsackievirus, rhinovirus, and enterovirus 71. Here, we show that enviroxime and GW5074 decreased PI4P levels at the Golgi complex by directly inhibiting PI4KIII&#x3b2;. Coxsackievirus mutants resistant to these inhibitors harbor single point mutations in the non-structural protein 3A. These 3A mutations did not confer compound-resistance by restoring the activity of PI4KIII&#x3b2; in the presence of the compounds. Instead, replication of the mutant viruses no longer depended on PI4KIII&#x3b2;, since their replication was insensitive to siRNA-mediated depletion of PI4KIII&#x3b2;. The mutant viruses also did not rely on other isoforms of PI4K. Consistently, no high level of PI4P could be detected at the replication sites induced by the mutant viruses in the presence of the compounds. Collectively, these findings indicate that through specific single point mutations in 3A, CVB3 can bypass an essential host factor and lipid for its propagation, which is a new example of RNA viruses acquiring resistance against antiviral compounds, even when they directly target host factors.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>van der Schaar</LastName><ForeName>Hilde M</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Department of Medical Microbiology, Virology Section, Nijmegen Centre for Molecular Life Sciences &amp; Nijmegen Institute for Infection, Inflammation and Immunity, Radboud University Nijmegen Medical Centre, 6500 HB Nijmegen, The Netherlands;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Linden</LastName><ForeName>Lonneke</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Lanke</LastName><ForeName>Kjerstin H W</ForeName><Initials>KH</Initials></Author><Author ValidYN="Y"><LastName>Strating</LastName><ForeName>Jeroen R P M</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>P&#xfc;rstinger</LastName><ForeName>Gerhard</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>de Vries</LastName><ForeName>Erik</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>de Haan</LastName><ForeName>Cornelis A M</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Neyts</LastName><ForeName>Johan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>van Kuppeveld</LastName><ForeName>Frank J M</ForeName><Initials>FJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>09</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Cell Res</MedlineTA><NlmUniqueID>9425763</NlmUniqueID><ISSNLinking>1001-0602</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001562">Benzimidazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007211">Indoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010091">Oximes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010636">Phenols</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018129">Phosphatidylinositol Phosphates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017361">Viral Nonstructural Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C037178">phosphatidylinositol 4-phosphate</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.1.-</RegistryNumber><NameOfSubstance UI="D017853">Phosphotransferases (Alcohol Group Acceptor)</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.1.67</RegistryNumber><NameOfSubstance UI="D019870">1-Phosphatidylinositol 4-Kinase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.1.67</RegistryNumber><NameOfSubstance UI="C581087">phosphatidylinositol 4-kinase IIIbeta, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>I5V34WG2BE</RegistryNumber><NameOfSubstance UI="C021595">viroxime</NameOfSubstance></Chemical><Chemical><RegistryNumber>P0LE4QW0S6</RegistryNumber><NameOfSubstance UI="C489251">5-iodo-3-((3,5-dibromo-4-hydroxyphenyl)methylene)-2-indolinone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D019870" MajorTopicYN="N">1-Phosphatidylinositol 4-Kinase</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001562" MajorTopicYN="N">Benzimidazoles</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029822" MajorTopicYN="N">Enterovirus B, Human</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006367" MajorTopicYN="N">HeLa Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007211" MajorTopicYN="N">Indoles</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010091" MajorTopicYN="N">Oximes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010636" MajorTopicYN="N">Phenols</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018129" MajorTopicYN="N">Phosphatidylinositol Phosphates</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017853" MajorTopicYN="N">Phosphotransferases (Alcohol Group Acceptor)</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017354" MajorTopicYN="N">Point Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D034622" MajorTopicYN="N">RNA Interference</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D034741" MajorTopicYN="N">RNA, Small Interfering</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017361" MajorTopicYN="N">Viral Nonstructural Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>9</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>9</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>5</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>11</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22945356</ArticleId><ArticleId IdType="pmc">PMC3494396</ArticleId><ArticleId IdType="doi">10.1038/cr.2012.129</ArticleId><ArticleId IdType="pii">cr2012129</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gern JE. The ABCs of rhinoviruses, wheezing, and asthma. J Virol. 2010;84:7418&#x2013;7426.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2897627</ArticleId><ArticleId IdType="pubmed">20375160</ArticleId></ArticleIdList></Reference><Reference><Citation>Mallia P, Contoli M, Caramori G, Pandit A, Johnston SL, Papi A. Exacerbations of asthma and chronic obstructive pulmonary disease (COPD): focus on virus induced exacerbations. Curr Pharm Des. 2007;13:73&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">17266589</ArticleId></ArticleIdList></Reference><Reference><Citation>Tebruegge M, Curtis N. Enterovirus infections in neonates. Semin Fetal Neonatal Med. 2009;14:222&#x2013;227.</Citation><ArticleIdList><ArticleId IdType="pubmed">19303380</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitton JL, Cornell CT, Feuer R. Host and virus determinants of picornavirus pathogenesis and tropism. Nat Rev Microbiol. 2005;3:765&#x2013;776.</Citation><ArticleIdList><ArticleId IdType="pubmed">16205710</ArticleId></ArticleIdList></Reference><Reference><Citation>Bible JM, Pantelidis P, Chan PK, Tong CY. Genetic evolution of enterovirus 71: epidemiological and pathological implications. Rev Med Virol. 2007;17:371&#x2013;379.</Citation><ArticleIdList><ArticleId IdType="pubmed">17487831</ArticleId></ArticleIdList></Reference><Reference><Citation>Bedard KM, Semler BL. Regulation of picornavirus gene expression. Microbes Infect. 2004;6:702&#x2013;713.</Citation><ArticleIdList><ArticleId IdType="pubmed">15158778</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinz BA, Vance LM. The antiviral compound enviroxime targets the 3A coding region of rhinovirus and poliovirus. J Virol. 1995;69:4189&#x2013;4197.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC189156</ArticleId><ArticleId IdType="pubmed">7769678</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinz BA and Vance LM. Sequence determinants of 3A-mediated resistance to enviroxime in rhinoviruses and enteroviruses. J Virol. 1996;70:4854&#x2013;4857.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC190432</ArticleId><ArticleId IdType="pubmed">8676522</ArticleId></ArticleIdList></Reference><Reference><Citation>Wikel JH, Paget CJ, DeLong DC, et al. Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-2-amine. Inhibitors of rhinovirus multiplication. J Med Chem. 1980;23:368&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pubmed">6247489</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown-Augsburger P, Vance LM, Malcolm SK, Hsiung H, Smith DP, Heinz BA. Evidence that enviroxime targets multiple components of the rhinovirus 14 replication complex. Arch Virol. 1999;144:1569&#x2013;1585.</Citation><ArticleIdList><ArticleId IdType="pubmed">10486111</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M, Wakita T, Shimizu H. Cellular kinase inhibitors that suppress enterovirus replication have a conserved target in viral protein 3A similar to that of enviroxime. J Gen Virol. 2009;90:1869&#x2013;1879.</Citation><ArticleIdList><ArticleId IdType="pubmed">19439558</ArticleId></ArticleIdList></Reference><Reference><Citation>De Palma AM, Thibaut HJ, van der Linden L, et al. Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307. Antimicrob Agents Chemother. 2009;53:1850&#x2013;1857.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2681499</ArticleId><ArticleId IdType="pubmed">19237651</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Franco D, Paul AV, Wimmer E. Tyrosine 3 of poliovirus terminal peptide VPg(3B) has an essential function in RNA replication in the context of its precursor protein, 3AB. J Virol. 2007;81:5669&#x2013;5684.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1900252</ArticleId><ArticleId IdType="pubmed">17360746</ArticleId></ArticleIdList></Reference><Reference><Citation>Towner JS, Mazanet MM, Semler BL. Rescue of defective poliovirus RNA replication by 3AB-containing precursor polyproteins. J Virol. 1998;72:7191&#x2013;7200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC109941</ArticleId><ArticleId IdType="pubmed">9696813</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonifacino JS, Glick BS. The mechanisms of vesicle budding and fusion. Cell. 2004;116:153&#x2013;166.</Citation><ArticleIdList><ArticleId IdType="pubmed">14744428</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MC, Miller EA, Goldberg J, Orci L, Schekman R. Bi-directional protein transport between the ER and Golgi. Annu Rev Cell Dev Biol. 2004;20:87&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pubmed">15473836</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabouille C, Klumperman J. Opinion: The maturing role of COPI vesicles in intra-Golgi transport. Nat Rev Mol Cell Biol. 2005;6:812&#x2013;817.</Citation><ArticleIdList><ArticleId IdType="pubmed">16167055</ArticleId></ArticleIdList></Reference><Reference><Citation>Cornell CT, Kiosses WB, Harkins S, Whitton JL. Inhibition of protein trafficking by coxsackievirus b3: multiple viral proteins target a single organelle. J Virol. 2006;80:6637&#x2013;6647.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1488957</ArticleId><ArticleId IdType="pubmed">16775351</ArticleId></ArticleIdList></Reference><Reference><Citation>Doedens JR, Kirkegaard K. Inhibition of cellular protein secretion by poliovirus proteins 2B and 3A. EMBO J. 1995;14:894&#x2013;907.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC398162</ArticleId><ArticleId IdType="pubmed">7889939</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu NY, Ilnytska O, Belov G, et al. Viral reorganization of the secretory pathway generates distinct organelles for RNA replication. Cell. 2010;141:799&#x2013;811.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2982146</ArticleId><ArticleId IdType="pubmed">20510927</ArticleId></ArticleIdList></Reference><Reference><Citation>Wessels E, Duijsings D, Notebaart RA, Melchers WJ, van Kuppeveld FJ. A proline-rich region in the coxsackievirus 3A protein is required for the protein to inhibit endoplasmic reticulum-to-golgi transport. J Virol. 2005;79:5163&#x2013;5173.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1069528</ArticleId><ArticleId IdType="pubmed">15795300</ArticleId></ArticleIdList></Reference><Reference><Citation>Belov GA, Feng Q, Nikovics K, Jackson CL, Ehrenfeld E. A critical role of a cellular membrane traffic protein in poliovirus RNA replication. PLoS Pathog. 2008;4:e1000216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2581890</ArticleId><ArticleId IdType="pubmed">19023417</ArticleId></ArticleIdList></Reference><Reference><Citation>Wessels E, Duijsings D, Niu TK, et al. A viral protein that blocks Arf1-mediated COP-I assembly by inhibiting the guanine nucleotide exchange factor GBF1. Dev Cell. 2006;11:191&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">16890159</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Angelo G, Vicinanza M, Di Campli A, De Matteis MA. The multiple roles of PtdIns(4)P &#x2013; not just the precursor of PtdIns(4,5)P2. J Cell Sci. 2008;121:1955&#x2013;1963.</Citation><ArticleIdList><ArticleId IdType="pubmed">18525025</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham TR, Burd CG. Coordination of Golgi functions by phosphatidylinositol 4-kinases. Trends Cell Biol. 2011;21:113&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3053015</ArticleId><ArticleId IdType="pubmed">21282087</ArticleId></ArticleIdList></Reference><Reference><Citation>Santiago-Tirado FH, Bretscher A. Membrane-trafficking sorting hubs: cooperation between PI4P and small GTPases at the trans-Golgi network. Trends Cell Biol. 2011;21:515&#x2013;525.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3164296</ArticleId><ArticleId IdType="pubmed">21764313</ArticleId></ArticleIdList></Reference><Reference><Citation>Blumental-Perry A, Haney CJ, Weixel KM, Watkins SC, Weisz OA, Aridor M. Phosphatidylinositol 4-phosphate formation at ER exit sites regulates ER export. Dev Cell. 2006;11:671&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pubmed">17084359</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorente-Rodriguez A, Barlowe C. Requirement for Golgi-localized PI(4)P in fusion of COPII vesicles with Golgi compartments. Mol Biol Cell. 2011;22:216&#x2013;229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3020917</ArticleId><ArticleId IdType="pubmed">21119004</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M, Wakita T, Shimizu H. Characterization of pharmacologically active compounds that inhibit poliovirus and enterovirus 71 infectivity. J Gen Virol. 2008;89:2518&#x2013;2530.</Citation><ArticleIdList><ArticleId IdType="pubmed">18796721</ArticleId></ArticleIdList></Reference><Reference><Citation>Balla A, Tuymetova G, Toth B, et al. Design of drug-resistant alleles of type-III phosphatidylinositol 4-kinases using mutagenesis and molecular modeling. Biochemistry. 2008;47:1599&#x2013;1607.</Citation><ArticleIdList><ArticleId IdType="pubmed">18205404</ArticleId></ArticleIdList></Reference><Reference><Citation>Knight ZA, Gonzalez B, Feldman ME, et al. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell. 2006;125:733&#x2013;747.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2946820</ArticleId><ArticleId IdType="pubmed">16647110</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M, Kojima H, Nagano T, Okabe T, Wakita T, Shimizu H. Phosphatidylinositol 4-kinase III beta is a target of enviroxime-like compounds for antipoliovirus activity. J Virol. 2011;85:2364&#x2013;2372.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3067798</ArticleId><ArticleId IdType="pubmed">21177810</ArticleId></ArticleIdList></Reference><Reference><Citation>Balla A, Tuymetova G, Tsiomenko A, Varnai P, Balla T. A plasma membrane pool of phosphatidylinositol 4-phosphate is generated by phosphatidylinositol 4-kinase type-III alpha: studies with the PH domains of the oxysterol binding protein and FAPP1. Mol Biol Cell. 2005;16:1282&#x2013;1295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC551492</ArticleId><ArticleId IdType="pubmed">15635101</ArticleId></ArticleIdList></Reference><Reference><Citation>Godi A, Di Campli A, Konstantakopoulos A, et al. FAPPs control Golgi-to-cell-surface membrane traffic by binding to ARF and PtdIns(4)P. Nat Cell Biol. 2004;6:393&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pubmed">15107860</ArticleId></ArticleIdList></Reference><Reference><Citation>He J, Scott JL, Heroux A, et al. Molecular basis of phosphatidylinositol 4-phosphate and ARF1 GTPase recognition by the FAPP1 pleckstrin homology (PH) domain. J Biol Chem. 2011;286:18650&#x2013;18657.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3099681</ArticleId><ArticleId IdType="pubmed">21454700</ArticleId></ArticleIdList></Reference><Reference><Citation>Toth B, Balla A, Ma H, Knight ZA, Shokat KM, Balla T. Phosphatidylinositol 4-kinase IIIbeta regulates the transport of ceramide between the endoplasmic reticulum and Golgi. J Biol Chem. 2006;281:36369&#x2013;36377.</Citation><ArticleIdList><ArticleId IdType="pubmed">17003043</ArticleId></ArticleIdList></Reference><Reference><Citation>Godi A, Pertile P, Meyers R, et al. ARF mediates recruitment of PtdIns-4-OH kinase-beta and stimulates synthesis of PtdIns(4,5)P2 on the Golgi complex. Nat Cell Biol. 1999;1:280&#x2013;287.</Citation><ArticleIdList><ArticleId IdType="pubmed">10559940</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahn RA, Volpicelli-Daley L, Bowzard B, et al. Arf family GTPases: roles in membrane traffic and microtubule dynamics. Biochem Soc Trans. 2005;33:1269&#x2013;1272.</Citation><ArticleIdList><ArticleId IdType="pubmed">16246095</ArticleId></ArticleIdList></Reference><Reference><Citation>Hausser A, Storz P, Martens S, Link G, Toker A, Pfizenmaier K. Protein kinase D regulates vesicular transport by phosphorylating and activating phosphatidylinositol-4 kinase IIIbeta at the Golgi complex. Nat Cell Biol. 2005;7:880&#x2013;886.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1458033</ArticleId><ArticleId IdType="pubmed">16100512</ArticleId></ArticleIdList></Reference><Reference><Citation>Bain J, Plater L, Elliott M, et al. The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007;408:297&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2267365</ArticleId><ArticleId IdType="pubmed">17850214</ArticleId></ArticleIdList></Reference><Reference><Citation>Lackey K, Cory M, Davis R, et al. The discovery of potent cRaf1 kinase inhibitors. Bioorg Med Chem Lett. 2000;10:223&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pubmed">10698440</ArticleId></ArticleIdList></Reference><Reference><Citation>Prudent R, Moucadel V, Lopez-Ramos M, et al. Expanding the chemical diversity of CK2 inhibitors. Mol Cell Biochem. 2008;316:71&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">18563535</ArticleId></ArticleIdList></Reference><Reference><Citation>Horiuchi KY, Wang Y, Diamond SL, Ma H. Microarrays for the functional analysis of the chemical-kinase interactome. J Biomol Screen. 2006;11:48&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">16314406</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M, Smith CJ, Walker MT, Smith TJ. Novel inhibitors complexed with glutamate dehydrogenase: allosteric regulation by control of protein dynamics. J Biol Chem. 2009;284:22988&#x2013;23000.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2755706</ArticleId><ArticleId IdType="pubmed">19531491</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine TP and Munro S. Targeting of Golgi-specific pleckstrin homology domains involves both PtdIns 4-kinase-dependent and -independent components. Curr Biol. 2002;12:695&#x2013;704.</Citation><ArticleIdList><ArticleId IdType="pubmed">12007412</ArticleId></ArticleIdList></Reference><Reference><Citation>Berger KL, Cooper JD, Heaton NS, et al. Roles for endocytic trafficking and phosphatidylinositol 4-kinase III alpha in hepatitis C virus replication. Proc Natl Acad Sci USA. 2009;106:7577&#x2013;7582.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2678598</ArticleId><ArticleId IdType="pubmed">19376974</ArticleId></ArticleIdList></Reference><Reference><Citation>Berger KL, Kelly SM, Jordan TX, Tartell MA, Randall G. Hepatitis C virus stimulates the phosphatidylinositol 4-kinase III alpha-dependent phosphatidylinositol 4-phosphate production that is essential for its replication. J Virol. 2011;85:8870&#x2013;8883.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3165839</ArticleId><ArticleId IdType="pubmed">21697487</ArticleId></ArticleIdList></Reference><Reference><Citation>Borawski J, Troke P, Puyang X, et al. Class III phosphatidylinositol 4-kinase alpha and beta are novel host factor regulators of hepatitis C virus replication. J Virol. 2009;83:10058&#x2013;10074.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2748049</ArticleId><ArticleId IdType="pubmed">19605471</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim YS, Hwang SB. Hepatitis C virus NS5A protein interacts with phosphatidylinositol 4-kinase type IIIalpha and regulates viral propagation. J Biol Chem. 2011;286:11290&#x2013;11298.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3064185</ArticleId><ArticleId IdType="pubmed">21297162</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiss S, Rebhan I, Backes P, et al. Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment. Cell Host Microbe. 2011;9:32&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3433060</ArticleId><ArticleId IdType="pubmed">21238945</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai AW, Benita Y, Peng LF, et al. A functional genomic screen identifies cellular cofactors of hepatitis C virus replication. Cell Host Microbe. 2009;5:298&#x2013;307.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2756022</ArticleId><ArticleId IdType="pubmed">19286138</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai AW, Salloum S. The role of the phosphatidylinositol 4-kinase PI4KA in hepatitis C virus-induced host membrane rearrangement. PLoS One. 2011;6:e26300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3192179</ArticleId><ArticleId IdType="pubmed">22022594</ArticleId></ArticleIdList></Reference><Reference><Citation>Trotard M, Lepere-Douard C, Regeard M, et al. Kinases required in hepatitis C virus entry and replication highlighted by small interference RNA screening. FASEB J. 2009;23:3780&#x2013;3789.</Citation><ArticleIdList><ArticleId IdType="pubmed">19608626</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie JM, Khromykh AA, Parton RG. Cholesterol manipulation by West Nile virus perturbs the cellular immune response. Cell Host Microbe. 2007;2:229&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pubmed">18005741</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin-Acebes MA, Blazquez AB, Jimenez de ON, Escribano-Romero E, Saiz JC. West Nile virus replication requires fatty acid synthesis but is independent on phosphatidylinositol-4-phosphate lipids. PLoS One. 2011;6:e24970.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3176790</ArticleId><ArticleId IdType="pubmed">21949814</ArticleId></ArticleIdList></Reference><Reference><Citation>Heaton NS, Perera R, Berger KL, et al. Dengue virus nonstructural protein 3 redistributes fatty acid synthase to sites of viral replication and increases cellular fatty acid synthesis. Proc Natl Acad Sci USA. 2010;107:17345&#x2013;17350.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2951450</ArticleId><ArticleId IdType="pubmed">20855599</ArticleId></ArticleIdList></Reference><Reference><Citation>Perera R, Riley C, Isaac G, et al. Dengue virus infection perturbs lipid homeostasis in infected mosquito cells. PLoS Pathog. 2012;8:e1002584.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3310792</ArticleId><ArticleId IdType="pubmed">22457619</ArticleId></ArticleIdList></Reference><Reference><Citation>Heaton NS, Randall G. Multifaceted roles for lipids in viral infection. Trends Microbiol. 2011;19:368&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3130080</ArticleId><ArticleId IdType="pubmed">21530270</ArticleId></ArticleIdList></Reference><Reference><Citation>Crotty S, Saleh MC, Gitlin L, Beske O, Andino R. The poliovirus replication machinery can escape inhibition by an antiviral drug that targets a host cell protein. J Virol. 2004;78:3378&#x2013;3386.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC371039</ArticleId><ArticleId IdType="pubmed">15016860</ArticleId></ArticleIdList></Reference><Reference><Citation>Belov GA, Kovtunovych G, Jackson CL, Ehrenfeld E. Poliovirus replication requires the N-terminus but not the catalytic Sec7 domain of ArfGEF GBF1. Cell Microbiol. 2010;12:1463&#x2013;1479.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2945620</ArticleId><ArticleId IdType="pubmed">20497182</ArticleId></ArticleIdList></Reference><Reference><Citation>Coelmont L, Hanoulle X, Chatterji U, et al. DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A. PLoS One. 2010;5:e13687.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2965138</ArticleId><ArticleId IdType="pubmed">21060866</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanke KH, van der Schaar HM, Belov GA, et al. GBF1, a guanine nucleotide exchange factor for Arf, is crucial for coxsackievirus B3 RNA replication. J Virol. 2009;83:11940&#x2013;11949.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772713</ArticleId><ArticleId IdType="pubmed">19740986</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed LJ, Muench H. A simple method of estimating fifty percent endpoints. Am J Hyg. 1938;27:493&#x2013;497.</Citation></Reference><Reference><Citation>Zhao XH, Bondeva T, Balla T. Characterization of recombinant phosphatidylinositol 4-kinase beta reveals auto- and heterophosphorylation of the enzyme. J Biol Chem. 2000;275:14642&#x2013;14648.</Citation><ArticleIdList><ArticleId IdType="pubmed">10799551</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung G, Barylko B, Lu D, Shu H, Yin H, Albanesi JP. Stabilization of phosphatidylinositol 4-kinase type IIbeta by interaction with Hsp90. J Biol Chem. 2011;286:12775&#x2013;12784.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3069477</ArticleId><ArticleId IdType="pubmed">21330372</ArticleId></ArticleIdList></Reference><Reference><Citation>van Kuppeveld FJ, Galama JM, Zoll J, Melchers WJ. Genetic analysis of a hydrophobic domain of coxsackie B3 virus protein 2B: a moderate degree of hydrophobicity is required for a cis-acting function in viral RNA synthesis. J Virol. 1995;69:7782&#x2013;7790.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC189721</ArticleId><ArticleId IdType="pubmed">7494289</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>